Advancements in Gene Therapy Safety: New Method for Detecting Viral Vector Exposure
For individuals and families navigating the challenges of inherited retinal diseases (IRDs), gene therapy offers a beacon of hope, promising to restore or preserve vision. As these innovative treatments advance, ensuring their safety for both patients and the wider community is paramount. Recent developments in detecting exposure risk from gene therapy viral vectors are a significant step forward in this commitment to safety.
Gene therapies for IRDs often utilize viral vectors, such as adeno-associated virus (AAV) vectors, to deliver corrective genetic material to the cells in the retina. While these vectors are engineered to be safe and effective within the patient, a key concern in gene therapy development is preventing the unintentional spread of these vectors to others. This is known as